These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20569520)

  • 21. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
    Mørk A; Pehrson A; Brennum LT; Nielsen SM; Zhong H; Lassen AB; Miller S; Westrich L; Boyle NJ; Sánchez C; Fischer CW; Liebenberg N; Wegener G; Bundgaard C; Hogg S; Bang-Andersen B; Stensbøl TB
    J Pharmacol Exp Ther; 2012 Mar; 340(3):666-75. PubMed ID: 22171087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand.
    Guo Y; Zhang H; Chen X; Cai W; Cheng J; Yang Y; Jin G; Zhen X
    Schizophr Res; 2009 Nov; 115(1):41-9. PubMed ID: 19744833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the 5-HT
    Mørk A; Russell RV; de Jong IE; Smagin G
    Eur J Pharmacol; 2017 Mar; 799():1-6. PubMed ID: 28188762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
    de Bruin NM; Prickaerts J; van Loevezijn A; Venhorst J; de Groote L; Houba P; Reneerkens O; Akkerman S; Kruse CG
    Neurobiol Learn Mem; 2011 Sep; 96(2):392-402. PubMed ID: 21757018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).
    Hirst WD; Andree TH; Aschmies S; Childers WE; Comery TA; Dawson LA; Day M; Feingold IB; Grauer SM; Harrison BL; Hughes ZA; Kao J; Kelly MG; van der Lee H; Rosenzweig-Lipson S; Saab AL; Smith DL; Sullivan K; Rizzo SJ; Tio C; Zhang MY; Schechter LE
    J Pharmacol Exp Ther; 2008 Apr; 325(1):134-45. PubMed ID: 18182558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
    Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
    Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
    Newman-Tancredi A; Verrièle L; Millan MJ
    Br J Pharmacol; 2001 Jan; 132(2):518-24. PubMed ID: 11159702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists.
    Rowley M; Hallett DJ; Goodacre S; Moyes C; Crawforth J; Sparey TJ; Patel S; Marwood R; Patel S; Thomas S; Hitzel L; O'Connor D; Szeto N; Castro JL; Hutson PH; MacLeod AM
    J Med Chem; 2001 May; 44(10):1603-14. PubMed ID: 11334570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.
    McLean SL; Idris NF; Woolley ML; Neill JC
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):440-50. PubMed ID: 19268547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.
    Grayson B; Idris NF; Neill JC
    Behav Brain Res; 2007 Nov; 184(1):31-8. PubMed ID: 17675172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition.
    Waters KA; Stean TO; Hammond B; Virley DJ; Upton N; Kew JN; Hussain I
    Behav Brain Res; 2012 Mar; 228(1):211-8. PubMed ID: 22189656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.
    McLean SL; Woolley ML; Thomas D; Neill JC
    Psychopharmacology (Berl); 2009 Oct; 206(3):403-14. PubMed ID: 19629447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration.
    Elsworth JD; Groman SM; Jentsch JD; Valles R; Shahid M; Wong E; Marston H; Roth RH
    Neuropharmacology; 2012 Mar; 62(3):1442-52. PubMed ID: 21875607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estradiol attenuates the cognitive deficits in the novel object recognition task induced by sub-chronic phencyclidine in ovariectomized rats.
    Roseman AS; McGregor C; Thornton JE
    Behav Brain Res; 2012 Jul; 233(1):105-12. PubMed ID: 22561127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
    Rossé G; Schaffhauser H
    Curr Top Med Chem; 2010; 10(2):207-21. PubMed ID: 20166958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
    Lieben CK; Blokland A; Sik A; Sung E; van Nieuwenhuizen P; Schreiber R
    Neuropsychopharmacology; 2005 Dec; 30(12):2169-79. PubMed ID: 15957009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia.
    Sood P; Idris NF; Cole S; Grayson B; Neill JC; Young AM
    J Psychopharmacol; 2011 Jun; 25(6):792-800. PubMed ID: 21088042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
    Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.